Origo Biopharma is a pharmaceutical company focused on the research and development of novel therapeutic products that modulate the immune system in order to obtain new treatments against diseases with an important immuno-inflammatory component such as cancer and fibrosis.
Our activity focuses on the discovery of new drugs that cover the needs of more effective treatments for these diseases.
Our mission is to discover and develop next-generation organ selective therapeutic products .
Our activity focuses on the discovery of new drugs that cover the needs of more effective treatments for these diseases.
Our mission is to discover and develop next-generation organ selective therapeutic products .
Location: Spain, Galicia, Touro
Employees: 1-10
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Asabys Par... | asabys.com... |
Mentions in press and media 3
| Date | Title | Description |
| 02.11.2021 | Agomab Therapeutics to Acquire Origo Biopharma | Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule dr... |
| 28.10.2021 | Agomab Therapeutics adquiere Origo Biopharma, participada por Asabys que desinvierte su participación | 28/10/2021 Nota de prensa AGOMAB THERAPEUTICS ADQUIERE ORIGO BIOPHARMA, PARTICIPADA POR ASABYS. • La adquisición refuerza el posicionamiento de Agomab como líder en el desarrollo de fármacos dirigidos a las vías de señalización de factor... |
| 07.07.2020 | Origo Biopharma cierra una ronda semilla de €2,3M liderada por Asabys. Participan XesGalicia y socios promotores | 07/07/2020 Nota de prensa ORIGO BIOPHARMA CIERRA UNA RONDA SEMILLA DE €2,3M LIDERADA POR ASABYS. PARTICIPAN XESGALICIA Y SOCIOS PROMOTORES. • Origo Biopharma, fundada en Galicia por GalChimia y Julio Castro (Palobiofarma), y actualmente ... |